Commercialization of nanotechnology

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 1, Issue 2, 2009, Pages 189-202

  Hobson, David W ^a  

^a ToxStrategies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DIAGNOSTICS; COMMERCIAL APPLICATIONS; DIAGNOSTIC IMAGING; MEDICAL PRACTICE; NANO PARTICULATES; NANOTECHNOLOGY INDUSTRY; PHARMACEUTICAL INDUSTRY; TECHNOLOGY COMMERCIALIZATIONS;

BIOCHEMISTRY; BIOMEDICAL EQUIPMENT; DIAGNOSIS; DRUG DELIVERY; INDUSTRY; MEDICAL APPLICATIONS; MEDICAL NANOTECHNOLOGY; NANOSTRUCTURED MATERIALS; PRODUCT DEVELOPMENT;

NANOTECHNOLOGY;

BIOTECHNOLOGY; ECONOMICS; INDUSTRY; INTERNATIONAL COOPERATION; MARKETING; NANOTECHNOLOGY; REVIEW;

BIOTECHNOLOGY; INDUSTRY; INTERNATIONALITY; MARKETING; NANOTECHNOLOGY;

EID: 77949329806     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.28     Document Type: Review

References (39)

1. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007, 3(1):95-101.
2. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against staphylococcus aureus and Escherichia coli. Nanomedicine 2007, 3(2):168-171.
3. Vlachou E, Chipp E, Shale E, Wilson YT, Papini R, et al. The safety of nanocrystalline silver dressings on burns: a study of systemic silver absorption. Burns 2007, 33(8):979-985.
4. Nohynek GJ, Lademann J, Ribaud C, Roberts MS. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol 2007, 37(3):251-277.
5. Crawley T. Report: Commercialisation of Nanotechnology-Key Challenges. Workshop organised by Nanoforum, Helsinki, Finland, 29th March, 2007.
6. Report: NANOtechnology: Untold promise, unknown risk. Consum Rep 2007, 72(7):40-45.
7. National Science Foundation: Societal Implications of Nanoscience and Nanotechnology. Arlington, VA: National Science Foundation; 2001, 272.
8. Report: Pharma 2020: Which path will you take? PricewaterhouseCoopers LLP 2007, 50.
9. Bunger M. Strategies for developing and commercializing nanobio drugs, diagnostics and devices. Nano Med 2007, 2(2):137-141.
10. Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci 2007, 96(10):2547-2565.
11. Ellis-Behnke RG, Teather LA, Schneider GE, So KF. Using nanotechnology to design potential therapies for CNS regeneration. Curr Pharm Des 2007, 13(24):2519-2528.
12. Zeineh MM, Zeineh RA.Miniature electrophoresis for speed and productivity. Appl Biochem Biotechnol 1990, 23(1):81-90.
13. Barkley PW, Seckler DW. Economic Growth and Environmental Decay: The Solution Becomes the Problem. New York: Harcourt Brace Jovanovich; 1972, 193.
14. Goldsmith R. Model of commercialization. http://asbdc.ualr.edu/technology/commercialization/themodel.asp (1999).
15. Nordan MM. Nanotech Commercialization has Advanced, but Government Action to Address Risk has not. Report Number NPS-T-06-001, Lux Research; 2006, 11.
16. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. The AAPS J 2007, 9(2):E128-E147.
17. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new Frontier in cancer chemotherapy. J Chemother 2004, 16(suppl 4):94-97.
18. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006, 1(3):297-315.
19. Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008, 25(1):55-71.
20. Drews J. Genomic sciences and the medicine of tomorrow. Nat Biotechnol 1996, 14(11):1516-1518.
21. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279(5349):377-380.
22. Putnam D, Gentry CA, Pack DW, Langer R. Polymerbased gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci USA 2001, 98(3):1200-1205.
23. Lynn DM, Langer R. Degradable Poly(ß-amino esters): Synthesis, characterization, and self-assembly with plasmid DNA. J Am Chem Soc 2000, 122:10761-10768.
24. Ledley FD. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 1995, 6:1129-1144.
25. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ: Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998, 15(2):270-275.
26. Santini J, Michael T Jr, Cima J, Langer R. Acontrolledrelease microchip. Nature 1999, 397:335-338.
27. Gref R, Minamitake Y, Peracchia MT, Trubetskoy VL, Torchilin VL, et al. Biodegradable long circulating polymeric nanospheres. Science 1994, 263:1600-1603.
28. Knop G, Münze R, Altenbrunn HJ. Preparation of tinalbumin nanospheres for labelling with 99mTc and application in liver scintigraphy. J Microencapsul 1984, 1(3):249-252.
29. Kobayashi H, Kawamoto S, Brechbiel MW, Bernardo M, Sato N, et al. Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle. Neoplasia 2005, 7(11):984-991.
30. Muldoon LL, Tratnyek PG, Jacobs PM, Doolittle ND, Christoforidis GA, Frank JA, Lindau M, Lockman PR, Manninger SP, Qiang Y, Spence AM, Stupp SI, Zhang M, Neuwelt EA. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: Report of the eleventh annual blood-brain barrier disruption consortium meeting. Am J Neuroradiol 2006, 27(3):715-721.
31. Kalman B, Lublin FD. The genetics of multiple sclerosis. A review. Biomed Pharmacother 1999, 53(8):358-370.
32. Gröndahl B, Puppe W, Hoppe A, Kühne I, Weigl JA, et al. Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study. J Clin Microbiol 1999, 37(1):1-7.
33. Perkal M, Marks C, Lorber MI, Marks WH. A threeyear experience with serum anodal trypsinogen as a biochemical marker for rejection in pancreatic allografts. False positives, tissue biopsy, comparison with other markers, and diagnostic strategies. Transplantation 1992, 53(2):415-419.
34. Koch M, Schmid FF, Zoete V, Meuwly M. Insulin: a model system for nanomedicine? Nano Med 2006, 1(3):373-378.
35. Borm PJ, Mü ller-Schulte D. Nanoparticles in drug delivery and environmental exposure: same size, same risks? Nano Med 2006, 1(2):235-249.
36. 36. Franco A, Hansen SF, Olsen SI, Butti L. Limits and prospects of the "incremental approach" and the European legislation on the management of risks related to nanomaterials. Regul Toxicol Pharmacol 2007, 48(2):171-183.
37. Tetley TD. Health effects of nanomaterials. Biochem Soc Trans 2007, 35(Pt 3):527-531.
38. Warheit DB, Borm PJ, Hennes C, Lademann J. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop. Inhal Toxicol 2007, 19(8):631-643.
39. DTI Report: An Overview of the Framework of Current Regulation Affecting the Development and Marketing of Nanomaterials. 2006, 191, www.berr.gov.uk/files/file36167.pdf.